Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Daniel O'Connor

MOHS-Micrographic Surgery Dover, NH Medical Doctor

NPI 1548792914 CMS profile 11314575

784 Central Ave, Dover, NH 03820

Open in the dashboard

General payments

$247

11 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel O'Connor of Dover, NH is reported in the CMS Open Payments database as having received $247 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 15th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $23 2
2024 General $31 2
2023 General $55 2
2022 General $137 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel O'Connor
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Daniel O'Connor were reported at $23. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Daniel O'Connor MOHS-Micrographic Surgery median Middle half National median
2019 $0 $316 $106–$785 $163
2020 $0 $162 $68–$412 $114
2021 $0 $243 $87–$654 $132
2022 $137 $300 $102–$887 $149
2023 $55 $364 $125–$1,010 $160
2024 $31 $445 $142–$1,108 $164
2025 $23 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Regeneron Healthcare Solutions, Inc. $69 2 payments
  2. Genzyme Corporation $36 1 payment
  3. Novartis Pharmaceuticals Corporation $33 1 payment
  4. Janssen Biotech, Inc. $33 2 payments
  5. MIMEDX Group, Inc. $31 2 payments
  6. Sun Pharmaceutical Industries Inc. $22 1 payment
  7. UCB, Inc. $21 1 payment
  8. Organon LLC $3 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $247 11 payments
Products named General payments · program years 2022–2025
  1. DUPIXENT Immunology $71 2 payments
  2. DUPIXENT Inflammation And Immunology $69 2 payments
  3. SIMPONI $33 2 payments
  4. SIMPONI ARIA $33 2 payments
  5. STELARA $33 2 payments
  6. REMICADE $33 2 payments
  7. ILUMYA $22 1 payment
  8. Bimzelx $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

101

Median for Dermatology: 534

Drug cost

$1,091

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gentamicin Sulfate Generic 15 $518
Cefadroxil Generic 48 $314
Doxycycline Hyclate Generic 21 $157
Mupirocin Generic 17 $101

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$558,090

Of which drugs: $104,024

Medicare patients

410

Average age 76

Services billed

2,012

183 women, 227 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 43%
Diabetes 23%
Ischemic heart disease 23%
Atrial fibrillation 21%
Chronic kidney disease 20%
Cancer 16%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Epieffect, per square centimeter Q4278 Office 13 237 $77,126
Epifix, per square centimeter Q4186 Office 13 224 $26,888

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record